FDA 官方药品与生物制品信息·AI 评分34
FDA近期发布的生物制品指南文件(2026年7—10月)
Recently Issued Biologics Guidance Documents
AI 导读
FDA近期发布多份生物制品相关指南文件,涵盖血压与脉搏供者资格合规政策、血液及血液成分捐献适用性与供者资格合规政策(均为CBER,2026年10月)。还包括2026年9月的缓冲层法制备血液成分采集处理储存系统建议,以及2026年8月的细胞与基因治疗产品开发常见问题、活性免疫治疗产品效价评估草案等。
正文 · 原文
Should you find a Web link (URL) embedded within guidance documents that does not work or other documents posted on the FDA Web site, please try searching for the document using the document title. If you need further assistance, please go to Contact FDA.
- Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy
CBER, October 2026 - Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements
CBER, October 2026 - Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method; Guidance for Industry
CBER, September 2026 - Electronic Submission Template for Premarket Approval Applications (PMA); Draft Guidance for Industry and Food and Drug Administration Staff
CDRH/CBER, September 2026 - Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products; Guidance for Industry
CBER, August 2026 - Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry
CBER, August 2026 - Container Closure Systems for Human Drugs and Biological Products; Draft Guidance for Industry
CDER/CBER/OCP, August 2026 - Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products; Guidance for Industry
CDER/CBER, August 2026 - Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts; Draft Guidance for Industry
CDER/CBER, July 2026 - Cancer Clinical Trial Eligibility Criteria: Laboratory Values; Guidance for Industry, IRBs, and Clinical Investigators
OCE/CDER/CBER, July 2026 - Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications; Guidance for Industry, IRBs, and Clinical Investigators
OCE/CDER/CBER, July 2026 Cancer Clinical Trial Eligibility Criteria: Performance Status; Guidance for Industry, IRBs, and Clinical Investigators
OCE/CDER/CBER, July 2026
来源:FDA 官方药品与生物制品信息 · fda.gov